Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States

Clinical Infectious Diseases

Volumn 52, Issue 6, 2011, Pages 695-706

  Hernandez, Jaime E ^a   Adiga, Raghavendra ^d   Armstrong, Robert ^e   Bazan, Jose ^g   Bonilla, Hector ^h   Bradley, John ^f   Dretler, Robin ⁱ   Ison, Michael G ^j   Mangino, Julie E ^g   Maroushek, Stacene ^k   Shetty, Avinash K ^b   Wald, Anna ^l   Ziebold, Christine ^m   Elder, Jenna ^c   Hollister, Alan S ^a   Sheridan, William ^a  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c Pharpoint Research   (United States)

^d Liberty Hospital   (United States)

^e Good Samaritan Hospital   (United States)

^f RADY CHILDREN'S HOSPITAL   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h SUMMA HEALTH SYSTEM   (United States)

ⁱ DeKalb Medical Center   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k HENNEPIN COUNTY MEDICAL CENTER   (United States)

^l UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^m UNIVERSITY OF IOWA CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYPERTENSIVE AGENT; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTINUOUS RENAL REPLACEMENT THERAPY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY TREATMENT; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH PROGRAM; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFANT; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MALE; PHYSICIAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; SCHOOL CHILD; SURVIVAL RATE; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRUS PNEUMONIA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; CYCLOPENTANES; DRUGS, INVESTIGATIONAL; FEMALE; GUANIDINES; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PREGNANCY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 79953766801     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir001     Document Type: Article

References (40)

1. Johnson CE. Determination that a public health emergency exists. Available at: http://www.flu.gov/professional/federal/h1n1emergency042609. html. Accessed 15 September 2010.
2. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-19.
3. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.
4. Dominguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 2009; 302:1880-7.
5. Centers for Disease Control and Prevention. Intensive-care patients with severe novel influenza A (H1N1) virus infection. Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009; 58:749-52.
6. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 in- fluenza virus infection during pregnancy in the USA. Lancet 2009; 374:451-8.
7. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283:1016-24. (Pubitemid 30112215)
8. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for the treatment of seasonal influenza. Antimicrob Agents Chermother 2010; 54:4568-74.
9. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Inf Dis 2007; 45:1568-75. (Pubitemid 351411840)
10. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalized with severe influenza. Thorax 2010; 65:510-5.
11. Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Available at: http://www.cdc.gov/h1n1flu/recommendations.htm. Accessed 15 May 2010.
12. Uyeki T. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med 2009; 361:e110 (ePub).
13. Bantia S, Parker CD, Ananth SL, Horn LL, Andries K, Chand P. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 2001; 45:1162-7. (Pubitemid 32230997)
14. Centers for Disease Control and Prevention. Emergency use authorization of peramivir IV fact sheet for health care providers. Available at: http://www.cdc.gov/h1n1flu/eua/pdf/final-hcp-fact-sheet-peramivirIV-CDC. pdf. Accessed 15 May 2010.
15. Bantia S, Kellogg D, Parker C, et al. A single intramuscular injection of peramivir demonstrates anti-influenza activity against recently isolated pandemic flu virus H1N1 (A/CA/04/2009). Antiviral Res 2010; 86:A29.
16. Yoshida R, Kodama M, Kobayashi M, Kitano M, Sato A, Yamano Y. Therapeutic effect of peramivir (S-021812, BCX-1812) after single intravenous treatment of mice infected with influenza A and B viruses [abstract V-1065]. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2009; 67.
17. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B infection in high-risk patients. Int J Infect Dis 2010; 14(suppl 1):e85-6.
18. Kohno S, Yen MY, Cheong JH, et al. Single-intravenous peramivir vs. oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: a Phase III randomized, double-blind trial [abstract V- 537a]. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2009; 38.
19. Ison MG, McGeer AJ, Hui DS, et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza [abstract V-6]. In: Abstracts of the XI International Symposium on Respiratory Viral Infections (Bangkok). New York, NY: The Macrae Group LLC, 2009.
20. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361:2204-7.
21. Bazan JA, Bauer KA, Hollister AS, et al. Pharmacokinetic monitoring of peramivir in two critically ill adult patients with 2009 H1N1 influenza A requiring continuous renal replacement therapy. Pharmacotherapy 2010; 30:1016-20.
22. Campbell AP, Jacob ST, Kuypers J, et al. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem cell transplantation recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. Ann Int Med 2010; 152:619-20.
23. Thomas B, Hollister AS, Muczynski KA. Peramivir clearance in continuous renal replacement therapy [letter]. Hemodial Int 2010; 14:336-40.
24. Beigel J, Harman LA, Collis PJ, et al. Pharmacokinetic and safety evaluations of escalating doses of peramivir administered intravenously in healthy volunteers [abstract A-1408]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.
25. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009; 302:1872-9.
26. Harms PW, Schmidt LA, Smith LB, et al. Autopsy findings in eight patients with fatal H1N1 influenza. Amer J Clin Pathol 2010; 134:27-35.
27. Swan S, Marbury T, Smith W, et al. Safety and pharmacokinetics of peramivir following intravenous administration in subjects with renal impairment [abstract 623]. In: Program and abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America (Philadelphia). Arlington, VA: IDSA, 2009; 73.
28. Sorbello A, Jones SC, Carter W, Struble K. the Peramivir Safety Team. [abstract V-648]. Program and abstracts of the 50th Interscience Conference on Antimicrobial agents and Chemotherapy (Boston). Washington, DC: American Society for Microbiology, 2010. 29.
29. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009; 83:10366-73.
30. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivirresistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034-41.
31. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360:953-6.
32. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 2007; 74:159-62. (Pubitemid 46436166)
33. Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res 2002; 54:143-7. (Pubitemid 34327680)
34. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivirresistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252-5.
35. Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010; 50:1493-6.
36. Centers for Disease Control and Prevention. Antiviral treatment options, including intravenous peramivir, for treatment of influenza in hospitalized patients for the 2009-2010 season. Available at: http://www.cdc.gov/h1n1flu/EUA/ peramivir-recommendations.htm. Accessed 15 May 2010.
37. Smee DF, Hurst B, Wong M-H, Tarbet EB, Babu YS, Morrey J. Efficacy of combinations of oseltamivir and peramivir in treating influenza a (H1N1) virus infections in cell culture and in mice. Antiviral Res 2010; 86:A47.
38. Lasseter K, Atiee G, Baughman S, et al. Absence of pharmacokinetic (PK) interaction between intravenous (IV) peramivir and oral (PO) rimantidine or oseltamivir in humans [abstract A1-2001]. In: Program and abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (Boston). Washington, DC: American Society for Microbiology, 2010.
39. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 4:e9332. doi:10.1371/journal.pone0009332
40. Ison MG, Gnann JW Jr., Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-90. (Pubitemid 36960891)